- Trials with a EudraCT protocol (470)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
		
	   		
	   		    
                    
                   	
                   	    470 result(s) found for: Cmin.
                    
                
			
   			
		
		Displaying page 1 of 24.
	
	
	| EudraCT Number: 2012-001142-18 | Sponsor Protocol Number: GS-EMC-001 | Start Date*: 2012-08-27 | 
| Sponsor Name:Erasmus MC | ||
| Full Title: Efficacy and pharmacokinetics of a switch from a regimen consisting of emtricitabine, nevirapine and tenofovir to rilpivirine, emtricitabine and tenofovir in virologically suppressed HIV-1 infected... | ||
| Medical condition: HIV AIDS | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-005640-34 | Sponsor Protocol Number: DFIDM-1501 | Start Date*: 2016-12-29 | |||||||||||
| Sponsor Name:CHIESI FARMACEUTICI S.P.A. | |||||||||||||
| Full Title: Envarsus® tablets administered once daily in combination with everolimus in elderly de-novo kidney transplant recipients: open-label, multicentre, single-arm, pharmacokinetic and clinical study | |||||||||||||
| Medical condition: Prophylaxis of organ transplant rejection | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001655-41 | Sponsor Protocol Number: 35RC19_8877_DIPLOID | Start Date*: 2020-09-15 | 
| Sponsor Name:CHU de Rennes | ||
| Full Title: P-glypoprotein inhibition effect on the pharmacokinetics of two tacrolimus formulations: prolonged and extended-release | ||
| Medical condition: healthy volunteers | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-004132-29 | Sponsor Protocol Number: Sobi.NTBC-003 | Start Date*: 2014-10-15 | |||||||||||
| Sponsor Name:Swedish Orphan Biovitrum AB (Publ) | |||||||||||||
| Full Title: An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnos... | |||||||||||||
| Medical condition: hereditary tyrosinemia type 1 | |||||||||||||
| 
 | |||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) DK (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-000506-78 | Sponsor Protocol Number: TIGE Pk 4-07 | Start Date*: 2007-05-16 | 
| Sponsor Name:Hannover Clinical Trial Center GmbH | ||
| Full Title: Monozentrische, prospektive, offene Studie zur Untersuchung der „steady state“-Pharmakokinetik von Tigecyclin im Plasma, im ELF und in Alveolarmakrophagen bei Intensivpatienten mit tiefer Atemwegsi... | ||
| Medical condition: Intensivpatienten mit tiefer Atemwegsinfektion | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-002695-94 | Sponsor Protocol Number: RALqd-ATV | Start Date*: 2008-07-21 | |||||||||||
| Sponsor Name:Fundació Lluita contra la SIDA | |||||||||||||
| Full Title: CLINICAL TRIAL ASSESSING ONCE DAILY RALTEGRAVIR ADMINISTRATION (800 mg QD) IN HIV-1-INFECTED PATIENTS RECEIVING UNBOOSTED ATAZANAVIR (400 mg QD)-BASED ANTIRETROVIRAL THERAPY (ENSAYO CLÍNICO PARA EV... | |||||||||||||
| Medical condition: Infección por VIH-1 (HIV-1 infection) | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004854-12 | Sponsor Protocol Number: N19RER | Start Date*: 2019-04-12 | |||||||||||
| Sponsor Name:Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | |||||||||||||
| Full Title: An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of CYP3A4 inhibitor Ritonavir on the Pharmacokinetics of Erlotinib | |||||||||||||
| Medical condition: Advanced EGFR mutation positive non small cell lung cancer, pancreatic carcinoma, colorectal cancer and biliary cancer | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-022293-14 | Sponsor Protocol Number: ANRS146OPTIMAL | Start Date*: 2012-08-22 | 
| Sponsor Name:Inserm-ANRS | ||
| Full Title: Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defi... | ||
| Medical condition: HIV infection | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-000307-24 | Sponsor Protocol Number: A0031005 | Start Date*: 2022-05-03 | 
| Sponsor Name:Pfizer Inc. | ||
| Full Title: AN OPEN LABEL NON-RANDOMIZED STUDY TO CHARACTERIZE THE STEADY STATE PHARMACOKINETICS OF SULFASALAZINE DELAYED RELEASE TABLETS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS | ||
| Medical condition: Juvenile Idiopathic Arthritis | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2006-004982-32 | Sponsor Protocol Number: LIPDEP-001 | Start Date*: 2007-06-27 | 
| Sponsor Name:Medical University of Vienna, Department of Pedatrics | ||
| Full Title: Cerebrospinal fluid (CSF) and plasma pharmocokinetics of liposomal cytarabine (DepoCyte®) after intrathecal administration in children with malignant brain tumors and leptomeningeal dissemination | ||
| Medical condition: To measure concentrations of liposomal cytarabine in CSF and plasma over time after intrathecal administration of liposomal cytarabine in children of different age groups with a malignant brain tum... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-005252-21 | Sponsor Protocol Number: N17PSI | Start Date*: 2017-04-13 | 
| Sponsor Name:Netherlands Cancer Institute | ||
| Full Title: Increasing pazopanib exposure by splitting intake moments | ||
| Medical condition: Patients for whom pazopanib is considered standard care (advanced renal cell carcinoma and advanced soft-tissue sarcoma). | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-002331-25 | Sponsor Protocol Number: BP27836 | Start Date*: 2011-12-07 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
| Full Title: An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Advanced Gastric Cancer | |||||||||||||
| Medical condition: HER2-positive adenocarcinoma of the stomach or gastroesophageal junction | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) BE (Completed) CZ (Completed) NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-004032-29 | Sponsor Protocol Number: M18CYP | Start Date*: 2019-01-23 | 
| Sponsor Name:Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital | ||
| Full Title: Effect of the moderate CYP3A4-inhibitor erythromycin on the pharmacokinetics of palbociclib | ||
| Medical condition: Patients for whom palbociclib is standard of care (breast cancer) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-004417-13 | Sponsor Protocol Number: CHUBX2018/65 | Start Date*: 2020-06-02 | 
| Sponsor Name:CHU de Bordeaux | ||
| Full Title: PROSPECTIVE RANDOMIZED CLINICAL TRIAL OF EARLY OXYBUTININ TREATMENT FOR BOYS WITH POSTERIOR URETHRAL VALVES | ||
| Medical condition: POSTERIOR URETHRAL VALVES | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-003174-50 | Sponsor Protocol Number: ALBUCEF | Start Date*: 2021-01-28 | 
| Sponsor Name:Medical University of Vienna Department of Cardiac Thoracic Vascular Anesthesia and Intensive Care Medicine | ||
| Full Title: The Effect of Albumin Levels on Pharmacokinetics of Cefazolin in Adult Cardiac Surgery: A Prospective, Randomized, Open-label, Parallel-group Pharmacokinetic Study | ||
| Medical condition: effect of hypoalbuminemia on pharmacokinetics of cefazolin | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-001605-42 | Sponsor Protocol Number: 20060317 | Start Date*: 2008-07-14 | |||||||||||
| Sponsor Name:Amgen Inc | |||||||||||||
| Full Title: A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Effi... | |||||||||||||
| Medical condition: Unrespectable locally advanced or metastatic gastric or esophagogastric unction adenocarcinoma | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) ES (Completed) IT (Prematurely Ended) GR (Completed) BE (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-023217-61 | Sponsor Protocol Number: 10/0174 | Start Date*: 2012-01-27 | |||||||||||
| Sponsor Name:University College London | |||||||||||||
| Full Title: A phase IV, open-label, partial cross-over partial parallel, randomized, multi-centre study to compare the gastrointestinal tolerability of once daily oral deferasirox, when administered before or ... | |||||||||||||
| Medical condition: transfusional haemosiderosis | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-001526-19 | Sponsor Protocol Number: BO27798 | Start Date*: 2011-12-28 | ||||||||||||||||
| Sponsor Name:F.Hoffmann-La Roche Ltd | ||||||||||||||||||
| Full Title: A randomized, open-label, multicenter Phase IIIb study comparing two trastuzumab dosing regimens, each in combination with cisplatin/ capecitabine chemotherapy, as first-line therapy in patients wi... | ||||||||||||||||||
| Medical condition: Metastatic HER2-positive adenocarcinoma of the stomach or gastro-esophageal junction. | ||||||||||||||||||
| 
 | ||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2022-000829-24 | Sponsor Protocol Number: 16 | Start Date*: 2023-08-09 | 
| Sponsor Name:ViiV Healthcare UK Limited | ||
| Full Title: Phase 1/2 Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children, 6 to less than 12 years of age, Living with HIV-1 | ||
| Medical condition: Virologically Suppressed Children, 6 to less than 12 years of age, Living with HIV-1 | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-002228-25 | Sponsor Protocol Number: D2615C00001 | Start Date*: 2015-11-10 | 
| Sponsor Name:AstraZeneca AB | ||
| Full Title: An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY) | ||
| Medical condition: Muscle-invasive bladder cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
 .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
 Query did not match any studies.
    	Query did not match any studies.
     
				
